Glatiramer acetate treatment in patients with childhood and juvenile onset multiple sclerosis

Neuropediatrics

Volumn 34, Issue 3, 2003, Pages 120-126

  Kornek, Barbara ^a   Bernert, G ^a   Balassy, C ^a   Geldner, J ^a   Prayer, D ^a   Feucht, M ^a  

^a UNIVERSITY OF VIENNA   (Austria)

Author keywords

Childhood onset; Glatiramer acetate; Multiple sclerosis

Indexed keywords

AZATHIOPRINE; CORTICOSTEROID; GLATIRAMER; IMMUNOGLOBULIN; MITOXANTRONE;

ADOLESCENT; AGE; ARTICLE; CLINICAL ARTICLE; COHORT ANALYSIS; CONTROLLED STUDY; DISABILITY; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; EVOKED VISUAL RESPONSE; FEMALE; FLUSHING; FOLLOW UP; HEART PALPITATION; HUMAN; INJECTION PAIN; MALE; MULTIPLE SCLEROSIS; NUCLEAR MAGNETIC RESONANCE IMAGING; ONSET AGE; PRIORITY JOURNAL; RECURRENT DISEASE; REMISSION; SIDE EFFECT;

ADJUVANTS, IMMUNOLOGIC; ADOLESCENT; BRAIN; CHILD; DIAGNOSIS, DIFFERENTIAL; DIPLOPIA; DISABILITY EVALUATION; EVOKED POTENTIALS, VISUAL; FEMALE; HUMANS; MAGNETIC RESONANCE IMAGING; MALE; MULTIPLE SCLEROSIS, RELAPSING-REMITTING; PEPTIDES; RECURRENCE;

EID: 0041733678     PISSN: 0174304X     EISSN: None     Source Type: Journal    
DOI: 10.1055/s-2003-41274     Document Type: Article

References (31)

1. Adams AB, Tyor WR, Holden KR. Interferon beta-1 b and childhood multiple sclerosis. Pediatr Neurol 1999; 21: 481-483
2. Balassy C, Bernert G, Wöber-Bingöl C, Csapo B, Kornek B, Szeles J et al. Long-term MRI observation of childhood-onset multiple sclerosis. Neuropediatrics 2001; 32: 28-37
3. Boiko A, Vorobeychik G, Paty D, Devonshire V, Sadovnick D, University of British Columbia MS Clinic Neurologists. Early onset multiple sclerosis: a longitudinal study. Neurology 2002; 59: 1006-1010
4. Brück W, Bitsch A, Kolenda H, Brück Y, Stiefel M, Lassmann H. Inflammatory central nervous system demyelination: Correlation of magnetic resonance imaging with lesion pathology. Ann Neurol 1997; 42: 783-793
5. Cole GF, Stuart CA. A long-term perspective on childhood multiple sclerosis. Dev Med Child Neurol 1995; 37: 661-666
6. Comi G, Filippi M, Wolinsky JS, and the European/Canadian Glatiramer Acetate Study Group. European/Canadian multicenter, double-blind, randomised, placebo-controlled study of the effects of glatiramer acetate on magnetic resonance imaging-measured disease activity and burden in patients with relapsing multiple sclerosis. Ann Neurol 2001; 49: 290-297
7. Comi G, Filippi M, Barkhof F, Durelli L, Edan G, Fernandez O et al. Early Treatment of Multiple Sclerosis Study Group. Effect of early interferon treatment on conversion to definite multiple sclerosis: a randomised study. Lancet 2001; 357: 1576-1582
8. Dale RC, de Sousa C, Chong WK, Cox TCS, Harding B, Neville BGR. Acute disseminated encephalomyelitis, multiphasic disseminated encephalomyelitis and multiple sclerosis in children. Brain 2000; 123: 2407-2422
9. Duquette P, Murray TJ, Pleines J. Multiple sclerosis in childhood: clinical profile in 125 patients. J Pediatr 1987; 111: 359-363
10. Ebers G. The natural history of multiple sclerosis. In: Compston A, Ebers G, Lassmann H, McDonalds I, Matthews B, Weherle H (Eds). McAlpines' Multiple Sclerosis. 3rd ed. London: Churchill Livingstone, 1998: 191-221
11. Filippi M, Rovaris M, Rocca MA, Sormani MP, Wolinsky JS, Comi G, and the European Canadian Glatiramer Acetate Study Group. Glatiramer acetate reduces the proportion of new MS lesions evolving into "black holes". Neurology 2001; 57: 731-733
12. Filippi M, Grossman RI. MRI techniques to monitor MS evolution: The present and the future. Neurology 2002; 58: 1147-1153
13. Ghezzi A, Deplano V, Faroni J, Grasso MG, Liguori M, Marrosu G et al. Multiple sclerosis in childhood: clinical features of 149 cases. Mult Scler 1997; 3: 43-46
14. Hanefeld FA. Characteristics of childhood multiple sclerosis. Int MSJ 1994; 1: 90-97
15. Jacobs LD, Beck RW, Simon JH, Kinkel RP, Brownscheidle CM, Murray TJ et al. Intramuscular interferon beta-1 a therapy initiated during a first demyelinating event in multiple sclerosis. CHAMPS Study Group. N Engl J Med 2000; 343: 898-904
16. Johnson KP, Brooks BR, Cohen JA, Ford CC, Goldstein J, Lisak RP et al, and the Copolymer I Multiple Sclerosis Study Group. Copolymer 1 reduces relapse rate and improves disability in relapsing-remitting multiple sclerosis: results of a phase III multicenter, double-blind, placebo-controlled trial. Neurology 1995; 45: 1268-1276
17. Johnson KP, Brooks BR, Cohen JA, Ford CC, Goldstein J, Lisak RP et al, and the Copolymer 1 Multiple Sclerosis Study Group. Extended use of glatiramer acetate (Copaxone) is well tolerated and maintains its clinical effect on multiple sclerosis relapse rate and degree of disability. Neurology 1998; 50: 701-708
18. Johnson KP, Brooks BR, Ford CC, Goodman A, Guarnaccia J, Lisak RP, and the Copolymer 1 Multiple Sclerosis Study Group. Sustained clinical benefits of glatiramer acetate in relapsing multiple sclerosis patients observed for 6 years. Mult Scler 2000; 6: 255-266
19. Kurtzke JF. Rating neurologic impairment in multiple sclerosis: an expanded disability status scale (EDSS). Neurology 1983; 33: 1444-1452
20. McDonald WI, Compston A, Edan G, Goodkin D, Hartung HP, Lublin FD et al. Recommended diagnostic criteria for multiple sclerosis: guidelines from the International Panel on the diagnosis of multiple sclerosis. Ann Neurol 2001; 50: 121-127
21. Mikaeloff Y, Moreau T, Debouverie M, Pelletier J, Lebrun C, Gout O et al. Interferon-β treatment in patients with childhood-onset multiple sclerosis. J Pediatr 2001; 139: 443-446
22. Pohl D, Hanefeld F. Multiple Sklerose bei Kindern und Jugendlichen. Akt Neurol 2001; 28: 8-11
23. Rosati G. The prevalence of multiple sclerosis in the world: an update. Neurol Sci 2001; 22: 117-139
24. Simone IL, Carrara D, Tortorella C, Liguori M, Lepore V, Pellegrini F et al. Course and prognosis in early-onset MS: comparison with adult-onset forms. Neurology 2002; 59: 1922-1928
25. Sindern E, Haas J, Stark E, Wurster U. Early onset MS under the age of 16: clinical and paraclinical features. Acta Neurol Scand 1992; 86: 280-284
26. Steinman L. Multiple sclerosis: a coordinated immunological attack against myelin in the central nervous system. Cell 1996; 85: 299-302
27. 1-weighted spin-echo MRI in multiple sclerosis. Neurology 1998; 50: 1282-1288
28. Waubant E, Hietpas J, Stewart T, Dyme Z, Herbert J, Lacy J et al. Interferon beta-1 a in children with multiple sclerosis is well tolerated. Neuropediatrics 2001; 32: 211-213
29. Weinshenker BG. Natural history of multiple sclerosis. Ann Neurol 1994; 36 (Suppl): S6-S11
30. Wolinsky JS, Comi G, Filippi M, Ladkani D, Kadosh S, Shifroni G, The European/Canadian Glatiramer Acetate Study Group. Copaxone's effect on MRI-monitored disease in relapsing MS is reproducible and sustained. Neurology 2002; 59: 1284-1286
31. Ziemssen T, Neuhaus O, Hohlfeld R. Risk-benefit assessment of glatiramer acetate in multiple sclerosis (review). Drug Safety 2001; 24: 979-990